{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"groups":[{"description":"Participants received eribulin mesylate 1.1 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 4 cycles, or until PD or unacceptable toxicity or DLT's.","id":"OG000","title":"Part A1: Eribulin Mesylate 1.1 mg/m^2"},{"description":"Participants received eribulin mesylate 1.4 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 8 cycles, or until PD or unacceptable toxicity or drug related DLT's.","id":"OG001","title":"Part A1: Eribulin Mesylate 1.4 mg/m^2"},{"description":"Participants received eribulin mesylate 1.8 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 5 cycles, or until PD or unacceptable toxicity or drug related DLT's.","id":"OG002","title":"Part A1: Eribulin Mesylate 1.8 mg/m^2"},{"description":"Participants received eribulin mesylate 1.4 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 2 cycles, or until PD or unacceptable toxicity or drug related DLT's for evaluation of PK.","id":"OG003","title":"Part A1: Eribulin Mesylate PK Expansion"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The SAS included all participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"First dose of study drug (Baseline) up to 30 days after last dose of study drug (Cycle 8 Day 38)","title":"Number of Participants With Clinically Significant Vital Sign Values","type":"PRIMARY","unitOfMeasure":"Participants"}